Loading…
JHS Svendgaard Laboratories (JHS)₹8.22+2.24%Personal Care
In the Jun 2026 quarter (consolidated), JHS Svendgaard Laboratories reported sales of ₹30.39 Cr, up 29.7% from Jun 2025, and net profit of ₹1.08 Cr, up 2.9% year on year. For the year to Mar 2026, sales were ₹102 Cr and net profit −₹1.99 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 18.91 | 14.29 | 21.65 | 24.46 | 19.67 | 22.68 | 25.16 | 23.44 | 22.30 | 23.26 | 32.68 | 30.39 |
| Expenses | 18.50 | 14.34 | 20.80 | 22.46 | 20.49 | 22.38 | 30.50 | 21.75 | 21.32 | 21.57 | 34.26 | 28.27 |
| Operating Profit | 0.42 | −0.05 | 0.85 | 1.98 | −0.85 | 0.26 | −5.39 | 1.67 | 0.92 | 1.68 | −1.63 | 2.08 |
| OPM % | 2.2% | −0.4% | 3.9% | 8.1% | −4.3% | 1.1% | −21.4% | 7.1% | 4.1% | 7.2% | −5.0% | 6.8% |
| Other Income | 0.19 | 2.33 | 1.36 | 0.31 | 0.85 | 0.26 | −1.43 | 0.99 | 1.13 | 0.58 | 0.72 | 0.08 |
| Interest | 0.09 | 0.10 | 0.12 | 0.11 | 0.10 | 0.12 | 0.20 | 0.15 | 0.19 | 0.27 | 0.21 | 0.27 |
| Depreciation | 1.49 | 1.62 | 1.89 | 1.96 | 1.97 | 1.96 | 2.01 | 1.87 | 1.85 | 1.89 | 1.85 | 1.81 |
| Profit before tax | −1.00 | 0.55 | 0.19 | 0.21 | −2.08 | −1.59 | −9.06 | 0.63 | −0.02 | 0.09 | −3.00 | 0.07 |
| Tax % | −26.2% | 100.1% | 516.7% | 415.0% | 398.1% | 15.8% | −23.1% | −69.3% | 1,800.0% | −887.4% | 19.8% | −1,716.7% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −2.85 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Profit | −0.72 | 0.00 | −0.74 | −0.62 | −10.30 | −1.83 | −6.94 | 1.05 | −0.19 | 0.78 | −3.56 | 1.08 |
| EPS (Rs) | −0.08 | 0.00 | −0.09 | −0.07 | −1.20 | −0.20 | −0.80 | 0.11 | −0.01 | 0.08 | −0.40 | 0.11 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 99.96 | 104 | 140 | 124 | 139 | 101 | 85.97 | 84.96 | 70.98 | 91.99 | 102 | 109 |
| Expenses | 92.82 | 91.93 | 126 | 124 | 137 | 98.81 | 86.86 | 93.79 | 71.94 | 95.83 | 98.77 | 105 |
| Operating Profit | 7.01 | 12.01 | 13.99 | 0.00 | 2.01 | 2.01 | −1.01 | −9.01 | −1.01 | −4.01 | 2.99 | 3.05 |
| OPM % | 7.0% | 11.0% | 10.0% | 0.1% | 1.2% | 1.9% | −1.0% | −11.0% | −1.3% | −4.4% | 2.6% | 2.8% |
| Other Income | −16.95 | 0.00 | 31.90 | 5.97 | 2.99 | 6.98 | 8.97 | −6.98 | 3.99 | 0.00 | 2.99 | 2.51 |
| Interest | 0.00 | 0.99 | 0.99 | 0.99 | 1.99 | 0.99 | 0.99 | 0.99 | 0.00 | 0.99 | 0.99 | 0.94 |
| Depreciation | 9.98 | 5.99 | 6.99 | 6.99 | 8.98 | 6.98 | 6.98 | 5.99 | 5.99 | 7.99 | 7.98 | 7.40 |
| Profit before tax | −22.03 | 5.01 | 38.04 | −2.01 | −6.01 | 1.01 | 0.00 | −23.03 | −3.01 | −13.01 | −2.01 | −2.86 |
| Tax % | 0.0% | −327.0% | 32.0% | −19.0% | −17.0% | −38.9% | 4,000.0% | −24.0% | 18.0% | 58.0% | −16.0% | — |
| Exceptional items | −17.96 | 0.00 | 17.98 | 0.00 | −8.99 | 0.00 | −0.99 | −18.98 | 0.00 | −0.99 | 0.00 | 0.00 |
| Net Profit | −21.95 | 21.97 | 25.94 | −1.99 | −4.99 | 0.99 | −3.99 | −17.97 | −3.99 | −19.95 | −1.99 | −1.89 |
| EPS (Rs) | −5.74 | 4.96 | 4.28 | −0.10 | −0.32 | 0.18 | −0.61 | 0.61 | −0.51 | −2.30 | −0.21 | −0.22 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 24.02 | 38.06 | 44.06 | 61.09 | 61.09 | 61.11 | 64.11 | 65.07 | 78.12 | 78.03 | 86.08 | 87.14 |
| Reserves | 95.90 | 62.96 | 89.95 | 113 | 116 | 117 | 124 | 121 | 94.94 | 90.95 | 86.90 | 86.86 |
| Borrowings | 18.97 | 2.99 | 1.99 | 1.99 | 7.00 | 8.98 | 7.00 | 5.99 | 2.99 | 4.99 | 5.99 | 14.99 |
| Other Liabilities | 33.02 | 18.95 | 19.04 | 32.04 | 39.18 | 55.17 | 33.16 | 30.15 | 52.25 | 22.03 | 25.07 | 26.08 |
| Total Liabilities | 171 | 122 | 155 | 208 | 223 | 241 | 228 | 222 | 228 | 197 | 204 | 215 |
| Fixed Assets | 108 | 64.92 | 64.94 | 70.97 | 70.97 | 65.98 | 62.95 | 58.92 | 64.99 | 89.92 | 89.92 | 88.94 |
| CWIP | 0.00 | 0.99 | 0.99 | 0.99 | 4.99 | 6.99 | 8.99 | 19.95 | 8.98 | 0.99 | 0.00 | 3.99 |
| Investments | 0.00 | 0.00 | 0.99 | 17.95 | 9.98 | 5.99 | 1.99 | 3.99 | 2.99 | 2.99 | 3.99 | 4.99 |
| Other Assets | 63.07 | 57.05 | 89.12 | 118 | 137 | 163 | 154 | 140 | 152 | 102 | 110 | 117 |
| Inventories | 10.01 | 11.01 | 11.01 | 10.01 | 10.01 | 6.01 | 12.01 | 12.02 | 13.01 | 13.02 | 15.02 | 15.02 |
| Trade receivables | 25.02 | 7.01 | 14.02 | 43.06 | 54.06 | 96.05 | 59.03 | 18.02 | 19.01 | 13.01 | 13.01 | 17.02 |
| Cash & equivalents | 0.99 | 2.99 | 5.99 | 5.99 | 0.99 | 0.99 | 20.96 | 5.99 | 38.95 | 9.98 | 19.98 | 18.95 |
| Total Assets | 171 | 122 | 155 | 208 | 223 | 241 | 228 | 222 | 228 | 197 | 204 | 215 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 7.02 | −4.01 | −4.01 | 14.02 | −11.03 | 10.02 | 12.03 | −9.01 | 23.06 | −9.02 | −5.01 | −3.01 |
| Cash from investing activity | 1.01 | 0.99 | −3.01 | −27.01 | −7.01 | −11.01 | −2.01 | −5.01 | 10.01 | −21.02 | −19.99 | −11.99 |
| Cash from financing activity | −9.99 | 3.99 | 9.99 | 13.99 | 12.98 | 0.00 | 9.99 | −1.99 | −0.99 | 1.99 | 22.99 | 10.99 |
| Net cash flow | −0.99 | 1.99 | 2.99 | 0.00 | −4.99 | 0.00 | 19.97 | −15.98 | 31.95 | −27.97 | −1.99 | −2.99 |
| Capex | 0.00 | 2.96 | 12.83 | 10.80 | 15.52 | 10.23 | 8.31 | 6.71 | 14.31 | 31.43 | 10.50 | 8.25 |
| Free cash flow | 8.97 | −6.98 | −16.95 | 2.99 | −25.93 | 0.00 | 4.98 | −15.96 | 20.96 | −32.91 | −13.96 | −14.95 |
| CFO / OP % | −189.1% | −58.1% | −33.1% | 118.9% | −10,000.1% | 594.9% | 650.0% | 1,050.9% | −257.0% | 1,000.9% | 121.9% | −77.1% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 167 | 25 | 48 | 111 | 158 | 252 | 213 | 77 | 80 | 66 | 52 | 60 |
| Inventory days | 94 | 53 | 95 | 65 | 60 | 30 | 97 | 114 | 128 | 176 | 153 | 85 |
| Days payable | 105 | 66 | 122 | 152 | 133 | 176 | 127 | 129 | 196 | 196 | 140 | 99 |
| Cash conversion cycle | 156 | 12 | 19 | 23 | 85 | 105 | 182 | 61 | 11 | 46 | 63 | 45 |
| Working capital days | −39 | 58 | 56 | 122 | 173 | 198 | 272 | 217 | 41 | 51 | 48 | 42 |
| ROCE % | −12.1% | −3.0% | 5.0% | 8.0% | 0.0% | 4.0% | 1.0% | 1.0% | −2.0% | −2.0% | −5.0% | −1.0% |
For the Jun 2026 quarter, JHS Svendgaard Laboratories reported sales of ₹30.39 Cr, up 29.7% year on year and net profit of ₹1.08 Cr, up 2.9% year on year. The operating margin was 6.8%.
JHS Svendgaard Laboratories' sales for the year to Mar 2026 were ₹102 Cr; over the last twelve months they were ₹109 Cr.
Net profit for the year to Mar 2026 was −₹1.99 Cr, and −₹1.89 Cr over the last twelve months. Earnings per share over the same trailing period were ₹−0.22.
JHS Svendgaard Laboratories reported borrowings of ₹14.99 Cr at Mar 2026, against cash and equivalents of ₹18.95 Cr.
Cash from operations was −₹3.01 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹14.95 Cr.